SWOG clinical trial number
A092204
A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer
Open
Abbreviated Title
Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer
Status Notes
The study is open to accrual.
Research committees
Early Therapeutics & Rare Cancers
Treatment
Cemiplimab
Cabozantinib
Eligibility Criteria Expand/Collapse
SWOG Cancer Research Network has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
SN2426
A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Sarcoma
Activated
01/28/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/AOST2032
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/17/2023
Open
SWOG Clinical Trial Number
CTSU/AOST2031
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/15/2022
Open